Abstract
Xenotransplantation may offer benefits to individual patients,but may also pose significant risks, to the recipient and to the public atlarge. The United States Food and Drug Administration endeavors to meet the challenge of regulating xenotransplantation to allow its development while safeguarding the public health. The approach includes using the existing FDA regulatory framework, publishing xenotransplantation-specific guidance documents, obtaining public input, and collaborating with other public health agencies and international bodies in order to develop and maintain a safe and rational program for the regulation of xenotransplantation.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Breimer ME (1999) Physiologic incompatibilities in discordant xenotransplantation.Transplant Proc 31:905–C908
Chapman LE (1999) Xenogeneic infections and public health. Clin Exp Pharmacol Physiol 26:1005–C1008
Chen S, Kahaku E, Watanabe F, Hewitt W, Eguchi S, Middleton Y, Arkadotoulos N, Rozga J, Solomon B, Demetriou A (1997) Treatment of severe liver failure with a bioartificial liver. Ann N YAcad Sci 831:350– 360
Dapolito G, Auchincloss H, Jr. (2000) Report of the Food and Drug Administration Subcommittee on Xenotransplantation: meeting of 13 January 2000, Center for Biologics Evaluation and Research. Xenotransplantation 7:75–79
Fink JS, Schumacher JM, Ellias SL, Palmer P, Saint-Hilaire M, Shannon K, Penn R, Starr P, VanHorne C, Kott HS, Dempsey PK, Fischman AJ, Raineri R, Manhart C, Dinsmore J, Isacson O (2000) Porcine xenografts in Parkinson_s disease and Huntington _s disease patients: preliminary results. Cell Transplant 9:273–278
Food and Drug Administration H (1993) Application of current statutory authorities to human somatic cell therapy products and gene therapy products. Federal Register 58:53248–53251
Goddard MJ, Foweraker JE (2000) Xenotransplantation - 2000. J Clin Pathol 53:44–48
Institute of Medicine (1996) Xenotransplantation: Science, Ethics, and Public Policy. National Academy Press, Washington, D.C. Lambrigts D, Sachs DH, Cooper DKC (1998) Discordant organ xenotransplantation in primates. World experience and current status. Transplantation 66:547–561
Logan JS (2000) Prospects for xenotransplantation. Curr Opin Immunol 12:563–568
Onions D, Witt CJ (2000) Xenotransplantation: an overview of microbiolgoical risks and potentials for risk management. Rev Sci Tech OIE 19:289–301
Paradis K, Langford G, Long Z, Heneine W, Sandstrom P, Switzer WM, Chapman LE, Lockey C, Onions D, The XEN 111 Study Group, Otto E (1999) Search for cross- 250 E. T. Bloom species transmission of porcine endogenous retrovirus in patients treated with living pig tissue. Science 285:1236–1241
Patience C, Takeuchi Y, Weiss RA (1997) Infection of human cells by an endogenous retrovirus of pigs. Nat Med 3:282–286
Pitkin Z, Mullon C (1999) Evidence of absence of porcine endogenous retrovirus (PERV) infection in patients treated with a bioartifical liver support system. Artif Organs 23:829–833
Tibell A. (2001) Regulating clinical xenotransplantation in Europe. Graft 4:157–159
United Network of Organ Sharing (1997) 1997 Report of the OPTN: Waiting List Activity and Donor Procurement, UNOS, Richmond, VA, and the Division of Transplantation, Office of Special Programs, Health Resources and Services Administration, U.S. Department of Health and Human Services, Rockville, Maryland.
U.S. Federal Statute (1938) Federal Food, Drug and Cosmetic Act, 21 U.S.C. 321(g), sect. 201(g)
U.S. Federal Statute (1944) Public Health Service Act, July 1, 1944, ch. 373, Title III, 351, 58 Stat. 702, currently codified at 42 U.S.C. 262.
U.S. Public Health Service (1996) Draft Public Health Service Guideline on infectious disease issues in xenotransplantation. Federal Register 61:49920–49932
van der Laan L, Lockey C, Griffeth BC, Frasier FS, Wilson CA, Onions DE, Hering BJ, Long Z, Otto E, Torbett BE, Salomon DR (2000) Infection by porcine endogenous retrovirus after islet xenotransplantation. Nature 407:90–94
Wang L, Sun J, Li L, Mears D, Horvat M, Sheil AGR (1998) Comparison of porcine hepatocytes with human hepatoma (C3A) cells for use in a bioartificial liver support system. Cell Transplant 7:459–468
Wilson CA, Wong S, Muller J, Davidson CE, Rose TM, Burd P (1998) Type C retrovirus released from porcine primary peripheral blood mononuclear cells infects human cells. J Virol 72:3082–3087
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Bloom, E.T. (2003). Xenotransplantation—Federal Regulatory Considerations. In: Salomon, D.R., Wilson, C. (eds) Xeno-transplantation. Current Topics in Microbiology and Immunology, vol 278. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-55541-1_9
Download citation
DOI: https://doi.org/10.1007/978-3-642-55541-1_9
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-62431-5
Online ISBN: 978-3-642-55541-1
eBook Packages: Springer Book Archive